Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
05 June 2020

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Sun Pharmaceuticals Industries Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 494.85
Net Changes 18.70
Volume 19100370
Prev Close 476.15
494.85 18.70 (3.93%)
Date: Jun 04,2020 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 474 Div Yield (%) 0.81
Buy (Size) 495.00(×1470) Eps(Rs) 13.38
Sell (Size) 497.00(×24) Book Value (Stand.)(Rs) 101.68
Value 29088628600 Book Value(conso.)(Rs) 188.6541649
Buy Quantity 1470 Market Cap(Rs.Cr) 118767.08
Sell Quantity 24 Face Value(Rs) 1
Today's High 497.8 Market Lot 1
Today's Low 472.4 AGM Date Aug
52-Week High 504.85 Book Closure Date Aug
52-Week Low 315.2 ISIN No. INE044A01036

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 1312134535 54.69
Total of Promoter 1312134535 54.69
Non Promoter (Institution) 776661677 32.37
Non Promoter (Non-Institution) 310538758 12.94
Total Non Promoter 1087200435 45.31
Total Promoter & Non Promoter 2399334970 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 2399334970 100.00

Company News

04-Jun-2020  Sun Pharmaceuticals Industries Ltd rises for third consecutive...
Sun Pharmaceuticals Industries Ltd rises for third consecutive session

Sun Pharmaceuticals Industries Ltd gained for a third straight session today. The stock is quoting at Rs 484.4, up 1.73% on the day as on 12:54 IST on the NSE. The benchmark NIFTY is down around 0.99% on the day, quoting at 9962.05. The Sensex is at 33797.72, down 0.91%. Sun Pharmaceuticals Industries Ltd has risen around 6.16% in last one month.

Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has risen around 8.53% in last one month and is currently quoting at 9864.05, up 1.02% on the day. The volume in the stock stood at 114.46 lakh shares today, compared to the daily average of 107.16 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 490.35, up 3.05% on the day. Sun Pharmaceuticals Industries Ltd is up 19.86% in last one year as compared to a 15.89% drop in NIFTY and a 20.36% drop in the Nifty Pharma index.

The PE of the stock is 35.58 based on TTM earnings ending March 20.

03-Jun-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on Jun 02, 2020. Total no. of equity shares bought back are 0
02-Jun-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Disclosure under SEBI Takeover Regulations

Sun Pharmaceutical Industries Limitedited has informed the Exchange regarding the disclosure pursuant to the provisions of Regulation 30 & 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as at 31st March, 2020
01-Jun-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on May 29, 2020. Total no. of equity shares bought back are 0
29-May-2020  Sun Pharma receives DCGI approval to initiate clinical trail w...
Sun Pharma receives DCGI approval to initiate clinical trail with Nafamostat Mesilate in Covid-19 patients

Sun Pharmaceuticals Industries has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).
29-May-2020  Sun Pharmaceuticals Industries Ltd - Announcement under Regula...
Sun Pharmaceuticals Industries Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release relating to approval from DCGI to initiate clinical trial with Nafamostat in Covid-19 patients, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,
29-May-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on May 28, 2020. Total no. of equity shares bought back are 0
28-May-2020  SPARC and Sun Pharma enter into licensing agreement for a pote...
SPARC and Sun Pharma enter into licensing agreement for a potential dermatology product

Sun Pharma Advanced Research Company and Sun Pharmaceutical Industries announced a worldwide licensing agreement on the development and commercialization of SCD-044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of US$ 20 million. SPARC will also be eligible to receive up to US$ 125 million as milestone payments contingent upon the achievement of clinical, regulatory and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.

28-May-2020  Sun Pharmaceuticals Industries Ltd - Announcement under Regula...
Sun Pharmaceuticals Industries Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find enclosed herewith our Press Release relating to license agreement for SCD-044 between Sun Pharma and SPARC.
28-May-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Press Release

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 27, 2020, titled 'Sun Pharma reports Q4FY20 results'.
Incorporation Year 1993 
Registered Office Sun Pharma Advanced Res.Centre,Tandalja,
Vadodara,
Gujarat-390020
Telephone 91-265-6615500 
Fax 91-265-2354897 
Chairman Israel Makov
Managing Director Dilip S Shanghvi
Company Secretary Sunil R Ajmera 
Auditor S R B C & Co LLP 
Face Value(Rs)
Market Lot
Listing BSE,MSEI,NSE 
Registrar Link Intime India Pvt Ltd
C-101 247 Park,L B S Marg,Vikhroli West,Mumbai-400083 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS